STRO — SUTRO BIOPHARMA, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1382101 ·
Last close
$8.92
Market Cap
$148.08M
52W High
$43.85
52W Low
$7.15
ADV30
336,899
Next earnings
—
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 9,098,000 — -21,940,000 -31,489,000 176,648,000 46,851,000 309,184,000
Jun 2026 9,839,000 — -29,687,000 -38,533,000 194,462,000 54,335,000 297,779,000
Mar 2026 14,523,000 — -29,614,000 -38,484,000 241,988,000 73,682,000 308,875,000
Dec 2025 11,647,000 — -33,657,000 -46,762,000 173,830,000 58,130,000 306,282,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-145,173,000
Investing CF
$32,788,000
Financing CF
$102,695,000
CapEx
$-532,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.37
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,054,972,000
Inventory
—
Receivables
$5,797,000
ST Investments
$110,011,000
EBIT TTM
$-139,151,000
Pretax Income TTM
$-180,732,000
Interest Exp TTM
$41,581,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$45,107,000
EBITDA
$-109,490,000
Free Cash Flow
$-105,745,376
Enterprise Value
$30,548,856
Total Cash
$142,176,992
Total Debt
$9,700,000
Shares Out
16,601,411
Trailing EPS
$-12.42
Book Value
$-7.99
ROE
—
ROA
-37.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 102,484,000 -104,952,000 -191,086,000 173,830,000 306,282,000 -132,452,000 -177,231,000
Dec 2024 62,043,000 -238,453,000 -227,461,000 387,207,000 342,606,000 44,601,000 -191,540,000
Dec 2023 153,731,000 -89,278,000 -106,793,000 470,736,000 321,087,000 149,649,000 -111,616,000
Dec 2022 67,772,000 -128,943,000 -119,204,000 406,944,000 189,896,000 217,048,000 3,549,000

TTM Snapshot

Revenues TTM
$45,702,000
NetIncome TTM
$-180,636,000
OpCashFlow TTM
—
Assets (Latest)
$194,462,000
Forward EPS
$-6.07

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $8.50 · call volume: 42 · put volume: 4

Peers — same industry

TickerNameMarket CapLastDaily %
IPHA Innate Pharma SA $148.56M $1.33 —
IVVD Invivyd, Inc. $151.09M $0.51 —
HUMA Humacyte, Inc. $139.18M $0.50 —
TARA Protara Therapeutics, Inc. $137.10M $2.32 —
IPHYF Innate Pharma SA $168.56M $1.51 —

News headlines (Yahoo Finance, 1h cache)

Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-12 21:30 · Yahoo
Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks
2026-11-04 13:35 · Yahoo
Sutro Biopharma to Participate in Upcoming Investor Conferences
2026-11-04 13:00 · Yahoo
Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround
2026-11-03 13:35 · Yahoo
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
2026-10-21 12:00 · Yahoo
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
2026-10-12 12:00 · Yahoo
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
2026-09-29 12:00 · Yahoo
STRO Stock Plummets 15% — What Drove The Selloff?
2026-08-12 20:07 · Yahoo
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
2026-08-12 11:00 · Yahoo
US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results
2026-05-17 13:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.